Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847068 | 1.00 | ACE (0.54) | ACE | |
| SCHEMBL4278365 | 1.00 | ACE (0.54) | ACE | |
| Guanidine SCHEMBL8691609 | 0.91 | ACE (0.47) | ACE | |
| Guanidine SCHEMBL8690711 | 0.91 | ACE (0.47) | ACE | |
| SCHEMBL3365538 | 0.87 | NOTUM (0.49) | ACE | |
| SCHEMBL8278527 | 0.86 | NOTUM (0.51) | ACE | |
| SCHEMBL10116501 | 0.86 | NOTUM (0.51) | ACE | |
| SCHEMBL12626587 | 0.84 | XIAP (0.47) | ACE | |
| SCHEMBL4271426 | 0.83 | ACE (0.56) | ACE | |
| SCHEMBL14610927 | 0.81 | ACE (0.47) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2015-02-12 | — | — | US | disclosed |
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | ACE 248/4885 |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | DDB1, CASP3, BAD | ACE 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.